Products & Services · Expense incurred by the collaboration
LEQEMBI — Expense incurred by the collaboration
Biogen LEQEMBI — Expense incurred by the collaboration decreased by 3.6% to $169.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.6%, from $177.70M to $169.50M. Over 3 years (FY 2022 to FY 2025), LEQEMBI — Expense incurred by the collaboration shows an upward trend with a 88.6% CAGR.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026
How to read this metric
Rising expenses indicate a scaling up of commercial or development activities, while declining expenses may signal a transition from high-cost development to commercial maturity.
Detailed definition
This metric captures the total operational and development expenses generated by a collaborative entity or joint venture...
Peer comparison
Comparable to total operating expenses of joint ventures or consolidated collaborative programs in the life sciences sector.
Metric ID:
biib_segment_leqembi_expense_incurred_by_the_collaborationHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $26.15M | $26.15M | $26.15M | $26.15M | $76.10M | $76.10M | $76.10M | $76.10M | $173.90M | $137.70M | $164.60M | $170.80M | $177.70M | $171.20M | $176.80M | $175.90M | $169.50M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +191.0% | +0.0% | +0.0% | +0.0% | +128.5% | -20.8% | +19.5% | +3.8% | +4.0% | -3.7% | +3.3% | -0.5% | -3.6% |
| YoY Change | — | — | — | — | +191.0% | +191.0% | +191.0% | +191.0% | +128.5% | +80.9% | +116.3% | +124.4% | +2.2% | +24.3% | +7.4% | +3.0% | -4.6% |
Range$26.15M – $177.70M
CAGR+59.6%
Avg YoY Growth+95.9%
Median YoY Growth+116.3%
Current Streak2 quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's leqembi — expense incurred by the collaboration?
- Biogen (BIIB) reported leqembi — expense incurred by the collaboration of $169.50M in Q1 2026.
- How has Biogen's leqembi — expense incurred by the collaboration changed year-over-year?
- Biogen's leqembi — expense incurred by the collaboration decreased by 4.6% year-over-year, from $177.70M to $169.50M.
- What is the long-term trend for Biogen's leqembi — expense incurred by the collaboration?
- Over 3 years (2022 to 2025), Biogen's leqembi — expense incurred by the collaboration has grown at a 88.6% compound annual growth rate (CAGR), from $104.60M to $701.60M.
- What does leqembi — expense incurred by the collaboration mean?
- The total expenses generated by a joint partnership for a specific product or program.